Skip to Content

Peptide-like hydrogels: A post-surgical sustained release drug delivery implant for the treatment of glioblastoma brain tumours

School of Pharmacy | PHD
Funding
Unfunded
Reference Number
PMY/2251/GL2
Application Deadline
31 January 2025
Start Date
1 October 2025

Overview

Glioblastoma is the most aggressive and malignant form of brain tumour with ~3,200 new cases annually within the UK and a median survival of 15 months. A technology that could locally deliver multiple anticancer drugs with independent modes of action to the irregular shapes of the resected tumour cavity would significantly improve patient outcomes e.g. reduced recurrence, improved quality of life and life expectancy. This project will overcome issues in current care by developing an advanced drug delivery implant composed of a peptide-like, peptoid-peptide hydrogel forming platform, which we recently published in the top Chemistry journal, the Journal of the American Chemical Society. This highly tunable formulation mimics naturally occurring peptides but with the additional benefit of enhanced stability within physiological environments, important for sustained drug delivery. Unlike existing polymer materials used in glioblastoma treatment, this technology exists as a fully soluble aqueous formulation which can be readily administered via syringe post-surgery to more effectively fill the resected tumour cavity. This then rapidly forms a soft hydrogel implant within the cavity. The hydrogel mimics the soft nature of healthy brain tissue reducing potential for adverse effects e.g. swelling. The aim of this project is to understand if an in situ forming hydrogel implant composed of peptoid-peptide hydrogels containing multiple anticancer drugs can be developed for use in glioblastoma treatment.

As a member of the Russell Group, Queen's University Belfast, which is consistently recognised as one of the leading universities for knowledge exchange in the UK, thus ensuring research is creating jobs, wealth, skills and innovation. The projects lead investigator Dr Laverty is a PhD graduate from the School of Pharmacy and has first-hand knowledge experience of the successful pathway a PhD from Queens University Belfast can provide. For this studentship the student will be trained in the following generic skills; developing writing skills, developing presentation skills, power point for academic presentations and posters, communication skills, introduction to research design, academic plagiarism, basic and advanced statistics, networking and negotiating, lab demonstrating and introduction to ref works. Students are also encouraged to use the Personal Development Planning (PDP) process to build a portfolio on learning, performance and achievement. PDP encourages the students to adopt a good work practice and supports the timely submission of thesis.



The student will receive formal training in the following specialist skills necessary for this project; peptide and peptoid synthesis, drug release protocols, confocal microscopy, scanning and transmission electron microscopy, tissue culture, HPLC, Fourier Transform infra-red spectrometry, circular dichroism, Mass Spectroscopy, NMR, neutron scattering techniques and use of in vivo facilities. The combination of these skills is highly transferable and should give the student a distinct advantage in the employment sector.



Healthcare Professionals/Regulators– This project will result in a novel drug delivery system that will serve as a superior alternative to existing formulations for healthcare professionals. The student will engage with individual consultants/physicians and drug regulators, providing knowledge input relating to clinical experimental design and result interpretation. We recognise it is important to instil healthcare practitioner confidence in the technology and obtain their feedback early in development.

Patients– The student will also engage with charities to provide stakeholder engagement activities (patient questionnaires, focus groups). We will explore: patient related factors; in-depth views on experiences and gauge their opinion on current treatments and our peptide-based platform.

-Involved in development of intellectual property

-Attendance at relevant conferences

-Engagement with industry and external collaborators

-Visits to large-scale neutron scattering facilities

-Generation of publications